1. Home
  2. TFIN vs TSHA Comparison

TFIN vs TSHA Comparison

Compare TFIN & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

TFIN

Triumph Financial Inc.

HOLD

Current Price

$73.02

Market Cap

1.7B

Sector

Finance

ML Signal

HOLD

Logo Taysha Gene Therapies Inc.

TSHA

Taysha Gene Therapies Inc.

HOLD

Current Price

$6.53

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TFIN
TSHA
Founded
1981
2019
Country
United States
United States
Employees
1450
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.8B
IPO Year
N/A
2020

Fundamental Metrics

Financial Performance
Metric
TFIN
TSHA
Price
$73.02
$6.53
Analyst Decision
Hold
Strong Buy
Analyst Count
5
8
Target Price
$66.20
$11.63
AVG Volume (30 Days)
205.2K
2.3M
Earning Date
04-21-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
5.56
EPS
N/A
N/A
Revenue
N/A
$9,773,000.00
Revenue This Year
$7.27
N/A
Revenue Next Year
$11.31
$1,152.42
P/E Ratio
$66.31
N/A
Revenue Growth
N/A
17.28
52 Week Low
$46.43
$2.25
52 Week High
$77.84
$7.30

Technical Indicators

Market Signals
Indicator
TFIN
TSHA
Relative Strength Index (RSI) 58.08 65.06
Support Level $60.93 $4.39
Resistance Level $77.84 $6.76
Average True Range (ATR) 2.45 0.38
MACD -0.18 0.11
Stochastic Oscillator 54.18 93.77

Price Performance

Historical Comparison
TFIN
TSHA

About TFIN Triumph Financial Inc.

Triumph Financial Inc is a financial holding company based in the United States. Along with its subsidiaries, the company operates in four reportable segments: Banking, Factoring, Payments, and Intelligence. The Banking segment, which generates maximum revenue, includes the operations of TBK Bank, offering traditional banking services. The Factoring segment provides working capital solutions to the trucking industry through the purchase of invoices generated by carriers at a discount. The Payments segment provides payment, audit, and other banking services for the over-the-road trucking industry, and the Intelligence segment operates to turn the over-the-road trucking data collected through the services offered into actionable insights for its customers.

About TSHA Taysha Gene Therapies Inc.

Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.

Share on Social Networks: